A Phase 2 open-label study in patients with recurrent Genotype 1 hepatitis C post-orthotopic liver transplant to explore the safety and efficacy of Simeprevir and Sofosbuvir with and without Ribavirin

-
Investigator: Norah A. Terrault, MD
Sponsor: Janssen Research & Development, a J&J Co

Location(s): United States

Description

A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin